Abstract
The steady state serum levels of disopyramide and its metabolite, mono-N-dealkylated disopyramide (MND) were measured by gas-liquid chromatography in 40 patients receiving maintenance disopyramide treatment. The levels were mean 3.11 micrograms/ml +/- 0.28 (s.e. mean) and 0.9 micrograms/ml +/- 0.13 (s.e. mean), respectively. A radioreceptor assay was used for the quantitation of the anticholinergic activity of disopyramide and its metabolite in the same serum samples. The serum levels of anticholinergic activity varied between 0 and 6.7 ng/ml when measured as atropine equivalent (mean 1.88 +/- 0.26, s.e. mean, ng/ml). After a single oral dose of disopyramide the serum anticholinergic activity was, however, not detectable or very low. There was a significant correlation between disopyramide concentrations in serum and the serum anticholinergic activity (r = 0.655, P less than 0.001). No correlation was found between MND concentrations and the anticholinergic activity arguing against the role of MND causing antimuscarinic side effects. The affinity of MND for the muscarinic receptors in vitro was also lower than that of disopyramide.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aaltonen L., Scheinin M. Application of radioreceptor assay of benzodiazepines for toxicology. Acta Pharmacol Toxicol (Copenh) 1982 Mar;50(3):206–212. doi: 10.1111/j.1600-0773.1982.tb00963.x. [DOI] [PubMed] [Google Scholar]
- Aitio M. L., Allonen H., Kanto J., Mäntylä R. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. Int J Clin Pharmacol Ther Toxicol. 1982 May;20(5):219–226. [PubMed] [Google Scholar]
- Aitio M. L. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite in plasma by gas-liquid chromatography. J Chromatogr. 1979 Dec 1;164(4):515–520. doi: 10.1016/s0378-4347(00)81556-x. [DOI] [PubMed] [Google Scholar]
- Aitio M. L., Virtanen R., Lammintausta R. Disopyramide concentrations in saliva. Int J Clin Pharmacol Ther Toxicol. 1982 Feb;20(2):68–72. [PubMed] [Google Scholar]
- Grant A. M., Marshall R. J., Ankier S. I. Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle. Eur J Pharmacol. 1978 Jun 15;49(4):389–394. doi: 10.1016/0014-2999(78)90313-8. [DOI] [PubMed] [Google Scholar]
- Iisalo E., Aaltonen L. Antimuscarinic side-effects of disopyramide. Lancet. 1983 Apr 30;1(8331):996–997. doi: 10.1016/s0140-6736(83)92124-4. [DOI] [PubMed] [Google Scholar]
- Kumana C. R., Rambihar V. S., Willis K., Gupta R. N., Tanser P. H., Cairns J. A., Wildeman R. A., Johnston M., Johnson A. L., Gent M. Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction. Br J Clin Pharmacol. 1982 Oct;14(4):529–537. doi: 10.1111/j.1365-2125.1982.tb02024.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakahara T., Hirano M., Uchimura H., Saito M., Kim J. S., Matsumoto T., Yokoo H., Shimomura M., Mukai A. Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment. Psychopharmacology (Berl) 1983;79(2-3):266–270. doi: 10.1007/BF00427825. [DOI] [PubMed] [Google Scholar]
- Nayler W. G. The pharmacology of disopyramide. J Int Med Res. 1976;4(1 Suppl):8–12. [PubMed] [Google Scholar]
- Tune L., Coyle J. T. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry. 1980 Mar;37(3):293–297. doi: 10.1001/archpsyc.1980.01780160063007. [DOI] [PubMed] [Google Scholar]